An article A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project WOS:000474446100008 published article about STAR-ASTERISK-D; MENTAL-HEALTH; LARGE-SCALE; DISORDER; EPIDEMIOLOGY; CLINICIAN; QUESTIONNAIRE; VALIDATION; INSTRUMENT; CITALOPRAM in [Jha, Manish K.; Grannemann, Bruce D.; Trombello, Joseph M.; Clark, E. Will; Eidelman, Sara Levinson; Greer, Tracy L.; Trivedi, Madhukar H.] Univ Texas Southwestern Med Ctr Dallas, Ctr Depress Res & Clin Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Jha, Manish K.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Jha, Manish K.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA; [Rush, A. John] Duke Natl Univ Singapore, Singapore, Singapore; [Rush, A. John] Duke Med Sch, Dept Psychiat, Durham, NC USA; [Rush, A. John] Texas Tech Univ, Hlth Sci Ctr, Permian Basin, TX USA in 2019.0, Cited 43.0. Formula: C4H14Cl2N2S2. The Name is 2,2′-Disulfanediyldiethanamine dihydrochloride. Through research, I have a further understanding and discovery of 56-17-7
PURPOSE This report describes outcomes of an ongoing quality-improvement project (VitalSign6) in a large US metropolitan area to improve recognition, treatment, and outcomes of depressed patients in 16 primary care clinics (6 charity clinics, 6 federally qualified health care centers, 2 private clinics serving low-income populations, and 2 private clinics serving patients with either Medicare or private insurance). METHODS Inclusion in this retrospective analysis was restricted to the first 25,000 patients (aged >= 12 years) screened with the 2-item Patient Health Questionnaire (PHQ-2) in the aforementioned quality-improvement project. Further evaluations with self-reports and clinician assessments were recorded for those with positive screen (PHQ-2 >2). Data collected from August 2014 though November 2016 were available at 3 levels: (1) initial PHQ-2 (n = 25,000), (2) positive screen (n = 4,325), and (3) clinician-diagnosed depressive disorder with 18 or more weeks of enrollment (n = 2,160). RESULTS Overall, 17.3% (4,325/25,000) of patients screened positive for depression. Of positive screens, 56.1% (2,426/4,325) had clinician-diagnosed depressive disorder. Of those enrolled for 18 or more weeks, 64.8% were started on measurement-based pharmacotherapy and 8.9% referred externally. Of the 1,400 patients started on pharmacotherapy, 45.5%, 30.2%, 12.6%, and 11.6% had 0, 1, 2, and 3 or more follow-up visits, respectively. Remission rates were 20.3% (86/423), 31.6% (56/177), and 41.7% (68/163) for those with 1, 2, and 3 or more follow-up visits, respectively. Baseline characteristics associated with higher attrition were: non-white, positive drug-abuse screen, lower depression/anxiety symptom severity, and younger age. CONCLUSION Although remission rates are high in those with 3 or more followup visits after routine screening and treatment of depression, attrition from care is a significant issue adversely affecting outcomes.
Bye, fridends, I hope you can learn more about C4H14Cl2N2S2, If you have any questions, you can browse other blog as well. See you lster.. Formula: C4H14Cl2N2S2
Reference:
Thiazine – an overview | ScienceDirect Topics,
,Thiazine | C4H5NS – PubChem